Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations

August 7, 2014

Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies

July 21, 2014

Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor

July 17, 2014

ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer’s Hallmarks in Preclinical Disease Model

July 14, 2014

Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds

June 30, 2014

M1 muscarinic agonists and a multipotent activator of sigma1/M1 muscarinic receptors: Future therapeutics of Alzheimer’s disease (AD)

June 10, 2014

Anavex Awarded New U.S. Patent

June 4, 2014

Anavex Appoints Dr. Abraham Fisher to Scientific Advisory Board

May 28, 2014

Anavex Reports That New Data Confirms Calcium Target Over-Expression May Be Involved in Causing Alzheimer’s Disease

May 22, 2014

Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in Alzheimer’s Disease

May 15, 2014

Anavex Strengthens Scientific Advisory Board with Clinical Trial Expert

May 12, 2014

Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors

May 8, 2014
1
23456789101112131415161718192021
…2223242526…
27282930313233343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top